- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
February 26, 2021Personal Injury and Medical Malpractice Partners Named to Minnesota Lawyer’s Power 30 List
-
February 22, 2021Robins Kaplan Expands Health Care Litigation Group
-
February 1, 2021Meegan Hollywood Selected to Join American Antitrust Institute Advisory Board
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
March, 9, 2021The New Frontier of Software License Disputes
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
February 26, 2021Financial Daily Dose 2.26.2021 | Top Story: Rising Long-Term Bond Yields Blamed for Jumpy Markets
-
February 25, 2021Financial Daily Dose 2.25.2021 | Top Story: McKinsey Ousts Managing Partner on Heels of Opioid Settlement
-
February 24, 2021Financial Daily Dose 2.24.2021 | Top Story: Chair Powell Promises Continued Fed Support for US Economy
Invokana and Farxiga
You must read the following notice before sending an e-mail message to Robins Kaplan LLP.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
For further inquiries about Invokanaand Farxiga, feel free to call us toll free at 1.800.553.9910, or send an e-mail by clicking on this link: contact us.
Invokana, Farxiga, and other related type 2 diabetes drugs have been linked to a serious condition known as ketoacidosis.
Diabetes Drug Update – Invokana and Farxiga
In May 2015, the FDA issued a Safety Communication advising that certain Type 2 Diabetes drugs may result in a serious condition known as ketoacidosis.
Holly Dolejsi of Robins Kaplan LLP Appointed Co-Lead Counsel in Farxiga Multidistrict Litigation
Judge Lorna G. Schofield has appointed Robins Kaplan attorney Holly Dolejsi as co-lead counsel in multidistrict litigation (MDL) involving the diabetes drug Farxiga.
Robins Kaplan LLP Investigates Type 2 Diabetes Drugs and Severe Injuries, Including Ketoacidosis
Invokana and other related type 2 diabetes drugs have been linked to a serious condition known as ketoacidosis.
Robins Kaplan LLP Attorney Holly Dolejsi Appointed to Plaintiffs’ Steering Committee for the Invokana Multidistrict
Judge Brian R. Martinotti of the District of New Jersey entered an order on Jan. 24 appointing Holly Dolejsi to the Plaintiffs’ Steering Committee for the Invokana multidistrict litigation.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.